Check out our new kidney biopsy episode with Prof. Kerstin Amann in 🇩🇪🇦🇹🇨🇭🇱🇮 language. Now available on YouTube.

The role of nutritional vitamin D in CKD-MBD in children and adults with CKD, on dialysis and after kidney transplantation – a European consensus statement by Drs. Jørgensen, @EvenepoelPieter et al. @NDTsocial

Anti-slit Antibodies against Podocin and Kirrel1 in Pediatric and Adult Podocytopathies by Drs.@RagliantiV , @PRomagnani et al. A study reporting anti-slit autoantibodies against podocin and Kirrel1 in a subset of patients with nephrotic syndrome.

MARKUS@HOMe wishes you a pleasant sunday!

Join our Webinar on YouTube about Lupus nephritis (in 🇩🇪🇦🇹🇨🇭🇱🇮 language) with our guest and expert Prof. Anders! @hjanders_hans Hosts: @gunnar_heine @sara___helena & Carolin Schneppe

Hardcore kidney disease for hardcore nephrologists: Renal Tubular Acidosis: Core Curriculum 2025 by @RWBonner91 and Gerald Hladik

Novel recommendation from the ERA Genes & Kidney Working Group Nephrectomy in Autosomal Dominant Polycystic Kidney Disease: A consensus statement @NDTsocial @ERAkidney

A peaceful sunday from MARKUS@HOMe.

Join our new webinar NOW on YouTube! Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY with our guests @doreen_zhu & Dr. Parminder Judge Moderators: Prof. Dr. Johannes Mann, @gunnar_heine, @MarcusSaemann

Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes by Drs. Bonnesen, @Morten__Schmidt et al. In a nationwise Danish cohort study, type 2 DM patients had similar kidney outcome with empagliflozin and dapagliflozin.

Anticoagulation and APT for Afib and Stable Coronary Disease by Drs. @SinaRsh, @bbikdeli et al. OAC mono, compared to OAC + SAPT, was not associated with a increased risk of ischemic events but resulted in a significantly reduced risk of bleeding events.

TOP 1: FLOW by Drs. @VladoPerkovic, @RpratleyMD et al. In patients with type 2 diabetes and chronic kidney disease, semaglutide reduced CKD progression and cardiovascular death.

Check out our webinar today on YouTube! Screening for atrial fibrillation: STROKESTOP II Dr. Kemp Gudmundsdottir discusses the prognostic implications of screening for atrial fibrillation, focusing upon her STROKESTOP II study.

Join our live event in Frankfurt a. Main! MARKUS at HOMe Unplugged Friday, 17.01.2025 4:30 pm

TOP 2: Felzartamab in ABMR by Drs. Mayer, @BohmigGeorg et al. In patients with antibody-mediated rejection, felzartamab had acceptable safety and side-effect profiles. Check out our webinar about Felzartamab! 👉

TOP 3: KDIGO CKD-Guidelines 2024

TOP 4: Antinephrin autoantibodies by Drs. @hengel_f , @Tobias_B_Huber et al. Circulating anti-nephrin Ab were common in patients with MCD or idiopathic NS, where they induce podocyte dysfunction and nephrotic syndrome and indicate disease activity.

TOP 5: EMPA-KIDNEY Long-Term Effects 2024 In CKD patients, empagliflozin had long-term cardiorenal benefits beyond the study end of EMPA-KIDNEY.

TOP 6: ADAPT by Drs. @DCharytan, Tumlin et al. In HD patients with hyperkalemia, combining dialysate K+ 3 mmol/l and SZC reduced AF rates compared with dialysate K+ 2 mmol/l.

Join our webinar NOW on YouTube. Part 2 of our top-rated studies in the field of nephrology and hypertensiology 2024. Our final countdown! Our guests: Timotheus Speer Matthias Girndt Mariam Abu-Tair